Skip to main content

Table 1 Study I: Characteristics of asthma patients grouped by EA and NEA

From: Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations

Characteristics

EA

NEA

t1/χ21/z1

P 1

F2/χ22/z2

P 2

Total

NA

PGA

n

44

71

40

31

    

Age, mean ± SD, yr

41.6 ± 12.5

48.6 ± 15.3

49.4 ± 15.6*

47.6 ± 15.2

−2.557

0.012

3.389

0.037

Gender, male n (%)

15 (34.1)

33 (46.5)

20 (50.0)

13 (41.9)

1.714

0.190

2.181

0.336

BMI, median (Q1, Q3), kg/m2

22.78 ± 4.11

24.04 ± 4.36

24.11 ± 4.65

23.96 ± 4.02

−1.539

0.127

1.185

0.310

Smoking, Current/Ex/Non

5/5/34

9/16/46

6/9/25

3/7/21

2.504

0.286

2.979

0.561

Smoking, pack-years

0.00 (0.00,0.00)

0.00 (0.00,7.70)

0.00 (0.00,7.70)

0.00 (0.00,8.80)

3.390

0.184

3.390

0.184

Age of asthma onset, mean ± SD, yr

33.73 ± 14.74

34.38 ± 19.18

32.65 ± 18.95

36.61 ± 19.54

−0.193

0.847

0.460

0.633

Asthma duration, median (Q1, Q3), yr

3.00 (1.25, 13.50)

7.00 (3.00, 23.00)

13.00 (4.50, 28.75)*

6.00 (2.00, 15.00)

−2.763

0.006

10.187

0.006

ICS dose, BDP equivalent, median (Q1, Q3), μg/d

400 (400, 400)

400 (400, 400)

400 (400, 400)

400 (400, 800)

−0.261

0.794

2.698

0.260

GINA steps 1–5, (n)

0/0/40/4/0

0/0/65/6/0

0/0/39/1/0

0/0/26/5

0.014

0.906

4.013

0.144

Medications, n (%)

 ICS/LABA

44 (100.0)

70 (98.6)

40 (100.0)

30 (96.8)

0.625

1.000

2.291

0.270

 LTRA

40 (90.9)

62 (87.3)

34 (85.0)

28 (90.3)

0.348

0.774

0.838

0.753

 Theophyline

7 (15.9)

13 (18.3)

7 (17.5)

6 (19.4)

0.109

0.741

0.151

0.952

 SABA

2 (4.5)

1 (1.4)

1 (2.5)

1 (3.2)

0.625

1.000

0.498

1.000

Spirometry, mean ± SD

 FEV1, L

2.27 ± 0.86

2.23 ± 0.93

2.12 ± 0.85

2.31 ± 0.99

0.233

0.816

0.261

0.771

 FVC, L

3.24 ± 0.96

3.18 ± 0.88

3.15 ± 0.84

3.21 ± 0.95

0.333

0.740

0.095

0.910

 FEV1, % predicted

73.51 ± 19.60

75.37 ± 20.46

72.76 ± 21.79

78.65 ± 18.47

−0.478

0.634

0.856

0.428

 FVC, % predicted

88.02 ± 13.92

90.80 ± 14.27

89.69 ± 15.31

92.19 ± 12.96

−1.021

0.309

0.788

0.457

 FEV1/FVC, %

69.40 ± 14.10

68.08 ± 15.26

66.20 ± 15.88

70.46 ± 14.36

0.460

0.647

0.823

0.442

ACQ scores, median (Q1, Q3)

1.0 (0.17, 1.63)

0.5 (0.0, 1.33)

0.5 (0.0, 1.33)

0.5 (0.0, 1.00)

2.259

0.109

2.259

0.109

AQLQ scores, mean ± SD

5.75 ± 0.80

5.99 ± 0.64

5.94 ± 0.64

6.07 ± 0.64

−1.765

0.080

1.835

0.164

FENO, median (Q1, Q3), ppb

53.0 (37.0, 80.0)

21.0 (15.0,32.0)

21.0 (15.0,33.0)*

21.5 (14.5, 30.25)*

5.444

< 0.001

6.544

0.002

IgE, median (Q1, Q3), IU/mL

258.3 (170.6, 537.5)

73.07 (28.66, 271.17)

108.6 (29.4, 403.2)

58.7 (27.5, 215.0)*

3.891

< 0.001

8.593

< 0.001

  1. ACQ asthma control questionnaire, AQLQ asthma quality of life questionnaire, BDP beclomethasone equivalents, BMI body mass index, FENO fractional exhaled nitric oxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GINA Global Initiative for Asthma, ICS inhaled corticosteroid, ICS/LABA inhaled corticosteroid with long-acting beta-agonist, LTRA leukotriene receptor antagonist, SABA short-acting beta-agonist, SD standard deviation, Q quartile, EA eosinophilic asthma, NEA non-eosinophilic asthma
  2. *Compared with eosinophilic-asthma, P < 0.05. t1 /χ21/z1 and P1: Compared between EA and NEA. F2/χ22/z2 and P2: Compared across EA, NA and PGA
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us